- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Tevogen Bio Inc: Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization | 91 | GlobeNewswire (Europe) | WARREN, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter... ► Artikel lesen | |
| Mi | Tevogen Bio Holdings reports Q1 results; operating loss falls 48% | 3 | Seeking Alpha | ||
| Mo | Tevogen reports reduced operating losses in 2025 and Q1 2026 | 1 | Investing.com | ||
| Mo | Tevogen Bio Inc: Letter to Shareholders from CEO Dr. Ryan Saadi | 58 | GlobeNewswire (Europe) | WARREN, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN). Dear Shareholders, Since Tevogen's 2024 public listing, we have remained focused on... ► Artikel lesen | |
| 15.05. | Tevogen Bio Holdings Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.05. | Tevogen Bio Inc: Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close | 252 | GlobeNewswire (Europe) | WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that it has entered into a securities purchase agreement for a private... ► Artikel lesen | |
| 30.04. | Tevogen Bio Holdings Inc. - 10-K/A, Annual Report | - | SEC Filings | ||
| TEVOGEN BIO Aktie jetzt für 0€ handeln | |||||
| 22.04. | Tevogen Bio Holdings Inc. - 8-K, Current Report | - | SEC Filings | ||
| 31.03. | Tevogen Bio Holdings Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 26.03. | Tevogen Bio Inc: Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth | 294 | GlobeNewswire (Europe) | Potential transaction expected to add $20M+ in revenue and support double-digit growth, further strengthening Tevogen's position in oncology, rare diseases, and medical devicesTarget CRO operates... ► Artikel lesen | |
| 25.03. | Tevogen Bio erfüllt nach Aktienzusammenlegung wieder Nasdaq-Anforderungen | 3 | Investing.com Deutsch | ||
| 25.03. | Tevogen Bio Holdings Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.03. | Tevogen Bio Inc: Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement | 200 | GlobeNewswire (Europe) | WARREN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) received written notice (the "Notification Letter") from The Nasdaq Stock Market... ► Artikel lesen | |
| 13.03. | Tevogen Bio Inc: Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization | 377 | GlobeNewswire (Europe) | Lead investor confirmed his intention to maintain his current shareholdings.Company does not anticipate using more than 1% of our authorized shares, including placement through the ATM, over the next... ► Artikel lesen | |
| 13.03. | Tevogen Bio Inc: Tevogen.AI Reports Advancements in PredicTcell Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure | 420 | GlobeNewswire (Europe) | WARREN, N.J., March 13, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced performance advancements for its artificial intelligence platform... ► Artikel lesen | |
| 11.03. | Tevogen Bio Inc: Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform | 2 | GlobeNewswire (USA) | ||
| 09.03. | Tevogen Bio Inc: Tevogen Names Leadership Team to Execute Diversified Growth Strategy | 401 | GlobeNewswire (Europe) | WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced the appointment of interim leaders across its core business verticals... ► Artikel lesen | |
| 06.03. | Tevogen Bio Inc: Letter to Shareholders from CEO Dr. Ryan Saadi | 701 | GlobeNewswire (Europe) | WARREN, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN). Dear Shareholders, As we continue executing on Tevogen's long-term strategy to evolve... ► Artikel lesen | |
| 06.03. | Tevogen Bio Explores Buyout To Boost Generics Platform | 6 | Benzinga.com | ||
| 06.03. | XFRA G280: AUSSETZUNG/SUSPENSION | 295 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILTEVOGEN BIO HLDGS... ► Artikel lesen |
1 2 3 4 Weiter >>
66 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,230 | +2,95 % | KAUFKURSE bei Renk und Desert Gold! SCHOCK bei der Evotec Aktie! | Während der Goldpreis schwächelt, befindet sich die Aktie von Desert Gold in einem sauberen Aufwärtstrend. Und geht es nach Analysten, ist eine Vervielfachung möglich. Denn Desert Gold wird in wenigen... ► Artikel lesen | |
| QIAGEN | 30,290 | +0,65 % | QIAGEN N.V.: QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA | Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights' curated biomedical knowledge bases Goal to advance how disease mechanisms... ► Artikel lesen | |
| MODERNA | 40,605 | -0,18 % | Moderna Flu Shot Heads To FDA Advisory Panel | ||
| VALNEVA | 2,501 | +0,16 % | Valneva Aktie: Prognose kassiert - die Börse schaut woanders hin | Valneva hat das erste Quartal 2026 mit einem deutlichen Umsatzrückgang abgeschlossen und die Jahresprognose gesenkt. Der Aktienkurs reagierte nicht entscheidend, denn der Markt richtet seinen Blick... ► Artikel lesen | |
| AMGEN | 292,50 | +0,72 % | Dividendenbekanntmachungen (15.05.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A10 NETWORKS INC US0021211018 0,06 USD 0,0514 EUR AF GRUPPEN ASA NO0003078107 6,5 NOK 0,6029 EUR AGCO CORPORATION US0010841023 0... ► Artikel lesen | |
| NOVAVAX | 7,830 | +1,29 % | Novavax, Inc.: Novavax Reports First Quarter 2026 Financial Results and Operational Highlights | Total revenue of $140 million in the first quarter of 2026
Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 14,380 | 0,00 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 545,80 | -1,32 % | Dividendenbekanntmachungen (20.05.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AFLAC INC US0010551028 0,61 USD 0,5255 EUR ARAMARK US03852U1060 0,12 USD 0,1033 EUR ARCHER DANIELS MIDLAND COMPANY US0394831020 0... ► Artikel lesen | |
| VIVOSIM LABS | 1,350 | +0,75 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,174 | +2,18 % | INOVIO Pharmaceuticals, Inc.: Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China | Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate
ApolloBio's... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo anticipates completing ST-920 BLA submission as early as this summer while appealing NASDAQ delisting in June | ||
| INTELLIA THERAPEUTICS | 10,920 | +2,44 % | Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry? | ||
| COSCIENS BIOPHARMA | 1,410 | +0,71 % | COSCIENS Biopharma Inc. - 6-K, Report of foreign issuer | ||
| BIOMARIN PHARMACEUTICAL | 46,890 | +0,75 % | BioMarin Pharmaceutical Inc.: BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO (vosoritide) in Children with Hypochondroplasia | Study met primary endpoint, exceeding expectations with a highly statistically significant improvement in annualized growth velocity (AGV, change from baseline)... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,840 | +0,52 % | Arbutus Biopharma Corporation: Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update | Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities... ► Artikel lesen |
TEVOGEN BIO HOLDINGS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -1,740 (-15,05 %) liegt der Kurs bei 9,825 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TEVOGEN BIO HOLDINGS INC finden Sie auf Wallstreet Online.